-
11:40:34 PM

ADGI Stock News

09/12/22 7:15 AM
Nasdaq : ADGI, IVVD
covid-19
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1 Antibodies target highly conserved
RHEA-AI
neutral
07/05/22 8:00 AM
Nasdaq : ADGI
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
Mithril Capital Management LLC, a founding investor in and the leader of a consortium of investors that represented approximately 49% of the outstanding shares of Adagio Therapeutics, Inc., today issued a letter to fellow Adagio shareholders thanking them for helping to ensure Adagio is best-positioned to advance its public health mission and build on the...
RHEA-AI
neutral
03/30/22 6:30 AM
Nasdaq : ADGI
covid-19
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy
RHEA-AI
neutral